<I do agree the market is a bit sensitive on any threats to eylea>
A bit? I think you are very mistaken here. It is extremely (I mean really extremely) sensitive (REGN MC and street sentiments) to Eylea performance.
And they are doing extremely pore (I mean really extremely) communication with Street and SHs/investors/traders about status and future perspective. AT JPM, all what they did, was REPEATING (I mean boringly repeating) how he and Yan were BODDY, from all days. Who care, and was that important how Eylea will compete and perform in 2018 and beyond? Not to mention that they were extremely (I mean extremely) stupid (I mean STUPID) not try to give decent forecast for 2018 sale. So, IF they are wrong, they are wrong. They can blame market dynamic. Also, not to mention that Eylea is extremely (I mean extremely) sensitive to CMC sentiments and regulation toward part B programs. What IF they LEGALIZE off-label Avastin????
Praluent (who knows what will CVOT do and be??) and Kevzara (no humira comparator in label, extremely stupid for REGN) going nowhere. Dupixent sale are so far so-so, brake-drug doing extremely pure in dermatology market (competitor gaining breakthrough on top of it????), ..what is left??? Asthma? also crowded! Spent all profit from Eylea on crowded PD-1/PD-L1 cancer programs...no guarantee that they can do BETTER than what is on market or what is coming???? Look what programs they are initiating????
For instance, why they are promoting BMY's PD-1/CTLA-4 regime in NSCLC? Hope the payer will substitute Opdivo with REGN2810, because it will be extremely cheaper??? Or maybe REGN2810 will outperform Opdivo??? Even, if it does (based on numbers)...there is little value because there in no direct comparison!
Now, maybe there is hope in RGC. Maybe?! Maybe it may help them to generate programs with known input (investment) and predictive outcome, that generate profit? They try to signal this to investors at JPM, BUT IF you do communicate....communicate with arguments. Not with story that few persons life were helped by gen-profiling. That is excellent as human example,...but they are not charity organizations, they are public company. So far they are short on this front as well.
So yes, ...a BIT SENSITIVE! |
